Respiratory syncytial virus-parainfluenza virus vaccine

Drug Profile

Respiratory syncytial virus-parainfluenza virus vaccine

Alternative Names: FRSV-HNPIV-3

Latest Information Update: 20 Jul 1998

Price : $50

At a glance

  • Originator Pharmacia Corporation; sanofi pasteur
  • Class Respiratory syncytial virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Parainfluenza virus infections; Respiratory syncytial virus infections

Most Recent Events

  • 20 Jul 1998 No-Development-Reported for Parainfluenza virus infections in USA (Unknown route)
  • 20 Jul 1998 No-Development-Reported for Respiratory syncytial virus infections in USA (Unknown route)
  • 18 Jan 1995 Preclinical development for Parainfluenza virus infections in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top